๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma
NCT05991856Aldosterone-producing Adenoma, Radiofrequency Ablation
Third Affiliated Hospital, Sun Yat-Sen University
Observational
45
Guangzhou
2020-01-01
Active, closed
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
NCT04194775Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Recruiting
Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
NCT04174079Thoracic Esophageal Squamous Cell Carcinoma
Sun Yat-Sen University Cancer Center
Not applicable
232
Guangzhou
2019-12-11
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia
NCT04143724Beta-Thalassemia
Celgene
Phase 2
99
Guangzhou, Shenzhen, Nanning, Chengdu
2019-11-07
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
Novartis Pharmaceuticals
Phase 1
120
Guangzhou
2019-10-30
Active, closed
Pd1 Antibody Sintilimab ยฑ Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT04304209Colorectal Cancer Stage II, Colorectal Cancer Stage III
Sun Yat-sen University
Phase 2
195
Guangzhou
2019-10-28
Recruiting
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 2
167
Shanghai, Guangzhou, Hangzhou
2019-10-18
Active, closed
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
NCT04127227NK/T Cell Lymphoma Nos
Sun Yat-sen University
Phase 2
34
Guangzhou
2019-10-09
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
NCT06155188Leukemia, Stem Cell Transplant, Cord Blood
Nanfang Hospital, Southern Medical University
Not applicable
60
Guangzhou
2019-09-29
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
Janssen Research & Development, LLC
Phase 2/3
1,064
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Beijing, Guangzhou, Changsha, Shanghai
2019-09-23
Active, closed
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04076059Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Recruiting
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
NCT04084496Pancreatic Cancer
Sun Yat-sen University
Phase 2
80
Guangzhou
2019-09-01
Recruiting
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
NCT05060796Non Small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase EARLY_PHASE1
11
Guangzhou
2019-09-01
Recruiting
RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
NCT04069884Breast Cancer, Radiation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
540
Guangzhou
2019-08-20
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
BeOne Medicines
Phase 3
510
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2019-08-20
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
NCT04015778Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 2
316
Guangzhou
2019-08-08
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Recruiting
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Active, closed
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
NCT04001777EGFR Positive Non-small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1
80
Guangzhou, Zhengzhou, Changchun
2019-07-04
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Guiyang, Haikou
2019-06-25
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Active, closed
Myopic Optic Neuropathy in Chinese High Myopia Population
NCT04302220Eye Diseases
Sun Yat-sen University
Observational
813
Guangzhou
2019-06-06
Recruiting
Endoscopic Anatomy of the Breast Fascia System
NCT06678776Breast Disease, Anatomy
Haiyan Li
Observational
184
Guangzhou
2019-06-01
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Recruiting
Tubeless NOSES Versus Laparoscopic Radical Resection for Rectosigmoid Cancers
NCT04037956Tubeless NOSES, Traditional Laparoscopic Radical Resection, Rectosigmoid Cancers
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
458
Guangzhou
2019-06-01
Active, closed
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977Urothelial Carcinoma
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Active, closed
Effisayilโ„ข ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
NCT03886246Generalized Pustular Psoriasis
LEO Pharma
Phase 2
131
Guangzhou, Hangzhou, Shanghai, Xi'an
2019-05-29
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953Lymphoma, Non-Hodgkin
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Recruiting
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
NCT03926338Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
270
Guangzhou
2019-05-10
Recruiting
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
NCT03398629Intrauterine Growth Restriction, Fetal Anomaly, Chromosomal Anomalies, Pregnancy
Guangzhou Women and Children's Medical Center
Observational
10,000
Guangzhou
2019-05-01
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
NCT04286841Immunotherapy, Lung Cancer
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Not yet open
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer
NCT03923335Colorectal Neoplasms
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
287
Guangzhou
2019-04-30
Recruiting
Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis
NCT03748485Colorectal Cancer, Adjuvant Chemotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
650
Guangzhou
2019-04-30
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Recruiting
Human Genes and Microbiota in Early Life
NCT06926166Host and Microbiome, Pregnancy Outcomes, Pregnancy Complications, Neurodevelopmental Disorders
Guangzhou Women and Children's Medical Center
Observational
20,000
Guangzhou
2019-04-01
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
NCT03869034Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Recruiting
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
NCT03872661Lung Cancer Stage III
Sun Yat-sen University
Phase 2
36
Guangzhou
2019-03-01
Recruiting
Tissue-engineered Skin Graft Repair of Autologous Scar Dermal Scaffolds
NCT04389164Scar
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
226
Guangzhou
2019-03-01
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Recruiting
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
NCT03920618Hepatitis B, Acute-On-Chronic Liver Failure
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
150
Guangzhou
2019-02-21
Active, closed
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)
NCT03847857Esophageal Anastomotic Leak
Sun Yat-sen University
Phase 3
360
Guangzhou, Jieyang, Shantou, Zhongshan, Chengdu, Shanghai
2019-02-21
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis
NCT03804931Ulcerative Colitis, Fecal Microbiota Transplantation
Guangzhou First People's Hospital
Phase 2/3
120
Guangzhou
2019-01-20
Recruiting
Toripalimab๏ผˆJS001๏ผ‰ as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
NCT03810339Solid Tumor, Advanced Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou, Guiyang, Wuhan, Dalian
2019-01-15
Active, closed
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
NCT04172259Breast Cancer, Neoadjuvant Chemotherapy
Sun Yat-sen University
Phase 2
156
Guangzhou
2019-01-10
Recruiting
Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors
NCT07357636Solid Tumor, Immune-Related Adverse Events, Immunotherapy Toxicity
Shantou University Medical College
Observational
940
Fuzhou, Guangzhou, Sanya, Shantou, Zhengzhou
2019-01-10
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
Genzyme, a Sanofi Company
Phase 3
281
Beijing, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2019-01-09
Recruiting
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
NCT03891706Solid Tumor
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
30
Guangzhou
2019-01-08
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Active, closed
Bidirectional Cohort Study on Improvement of Quality of Life in Patients After Coronary Intervention With Kuanxiong Aerosol
NCT06480097Angina Pectoris, Kuanzhong Aerosol, Quality of Life, Cardiac Function
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou
2019-01-01
Recruiting
Dolutegravir Plus Lamivudine Simplified Therapy
NCT03884673HIV/AIDS
Guangzhou 8th People's Hospital
Observational
300
Guangzhou
2019-01-01
Recruiting
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
NCT03882840Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
60
Guangzhou
2019-01-01
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
Daiichi Sankyo
Phase 3
557
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Nanjing, Changchun
2018-12-27
Active, closed
TNT to Increase the Clinical Complete Response Rate for Distal LARC
NCT03840239Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III, Chemoradiation
Sun Yat-sen University
Phase 2
98
Guangzhou
2018-12-25
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Recruiting
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
NCT03587480Rectal Neoplasm Malignant
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
250
Guangzhou
2018-12-17
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637Triple Negative Breast Cancer
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2018-11-27
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Recruiting
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
NCT03671252Rectal Cancer
Sun Yat-sen University
Phase 3
776
Guangzhou
2018-11-16
Recruiting
Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation
NCT03059043Myopia
Wenzhou Medical University
Not applicable
60
Guangzhou, Changsha, Wenzhou, Beijing, Shanghai
2018-11-16
Recruiting
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
NCT03769129Non Small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
100
Guangzhou
2018-11-01
Recruiting
Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)
NCT03180320Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Guangdong Provincial Hospital of Traditional Chinese Medicine
Not applicable
150
Guangzhou
2018-10-22
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
NCT03736889MSI-H/dMMR Solid Tumors
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Recruiting
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
NCT03613545Irritable Bowel Syndrome, Fecal Microbiota Transplantation
Guangzhou First People's Hospital
Phase 2/3
120
Guangzhou
2018-08-10
Active, closed
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110Breast Cancer
Daiichi Sankyo
Phase 3
524
Beijing, Guangzhou, Harbin, Changchun, Shenyang, Shanghai, Chengdu, Tianjin
2018-08-09
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai
2018-08-09
Recruiting
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
NCT03561740Breast Cancer
Sun Yat-sen University
Phase 3
794
Guangzhou
2018-07-25
Active, closed
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
NCT03521154Non Small Cell Lung Cancer (Stage III)
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Rows per page Showing 3101–3200 of 3318
Previous 30 31 32 33 34 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=32

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.